Starving tumors: Inhibition of glycolysis reduces viability of human endometrial and ovarian cancer cells and enhances antitumor efficacy of GnRH receptor-targeted therapies

International Journal of Gynecological Cancer

Volumn 23, Issue 1, 2013, Pages 34-40

  Reutter, Madita ^a   Emons, Günter ^a   Gründker, Carsten ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

2 Deoxy D Glucose; Cotreatment; GnRH receptor; Targeted therapy

Indexed keywords

CASPASE 3; GONADORELIN ANTAGONIST;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA FRAGMENTATION; ENDOMETRIUM CANCER; ENZYME ACTIVATION; ENZYME ACTIVITY; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; NICK END LABELING; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, ENDOMETRIOID; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYGLUCOSE; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; ENDOMETRIAL NEOPLASMS; FEMALE; GLYCOLYSIS; HUMANS; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; RECEPTORS, LHRH; STARVATION; TREATMENT OUTCOME;

EID: 84872331604     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318275b028     Document Type: Article

References (34)

1. Chen Z, Lu W, Garcia-Prieto C, et al. The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr. 2007;39:267-274.
2. Warburg O. The Metabolism of Tumors. London: Constable; 1930.
3. Yamamoto T, Seino Y, Fukumoto H, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun. 1990;170:223-230.
4. Pelicano H, Martin DS, Xu RH, et al. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25:4633-4646.
5. Kaplan O, Navon G, Lyon RC, et al. Effects of 2-deoxyglucose on drug-sensitive and drug-resistant human breast cancer cells: toxicity and magnetic resonance spectroscopy studies of metabolism. Cancer Res. 1990;50:544-551.
6. Laszlo J, Humphreys SR, Goldin A. Effects of glucose analogues (2-deoxy-D-glucose, 2-deoxy-D-galactose) on experimental tumors. J Natl Cancer Inst. 1960;24:267-281.
7. Aft RL, Zhang FW, Gius D. Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death. Br J Cancer. 2002;87:805-812.
8. Bell SE, Quinn DM, Kellett GL, et al. 2-Deoxy-D-glucose preferentially kills multidrug-resistant human KB carcinoma cell lines by apoptosis. Br J Cancer. 1998;78: 1464-1470.
9. Lee YJ, Galoforo SS, Berns CM, et al. Glucose deprivation-induced cytotoxicity in drug resistant human breast carcinoma MCF-7/ADR cells: role of c-myc and bcl-2 in apoptotic cell death. J Cell Sci. 1997;110:681-686.
10. Landau BR, Lubs HA. Animal responses to 2-deoxy-D-glucose administration. Proc Soc Exp Biol Med. 1958;99:124-127.
11. Gründker C, Günthert AR, Westphalen S, et al. Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol. 2002;146:1-14.
12. Emons G, Ortmann O, Schulz KD, et al. Growth inhibitory actions of luteinizing hormone-releasing hormone on tumor cells. Trends Endocrinol Metab. 1997;8:355-362.
13. Emons G, Schally AV. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum Reprod. 1994;9:1364-1379.
14. Emons G, Sindermann H, Engel J, et al. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152. Neuroendocrinology. 2009;90:15-18.
15. Günthert AR, Gründker C, Bongertz T, et al. Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system. Breast Cancer Res Treat. 2004;87:255-264.
16. Günthert AR, Gründker C, Bongertz T, et al. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system. Am J Obstet Gynecol. 2004; 191:1164-1172.
17. Westphalen S, Kotulla G, Kaiser F, et al. Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines. Int J Oncol. 2000;17:1063-1069.
18. Fister S, Günthert AR, Emons G, et al. Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo. Cancer Res. 2007;67:1750-1756.
19. Fister S, Günthert AR, Aicher B, et al. GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax. Cancer Res. 2009;69:6473-6481.
20. Gründker C, Günthert AR, Millar RP, et al. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J Clin Endocrinol Metab. 2002;87:1427-1430.
21. Eicke N, Günthert AR, Viereck V, et al. GnRH-II receptor-like antigenicity in human placenta and in cancers of the human reproductive organs. Eur J Endocrinol. 2005;153:605-612.
22. Eicke N, Günthert AR, Emons G, et al. GnRH-II agonist [D-Lys6]GnRH-II inhibits the EGF-induced mitogenic signal transduction in human endometrial and ovarian cancer cells. Int J Oncol. 2006;29:1223-1229.
23. Emons G, Ortmann O, Becker M, et al. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res. 1993;53:5439-5446.
24. Emons G, Schröder B, Ortmann O, et al. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab. 1993;77:1458-1464.
25. Irmer G, Bürger C, Müller R, et al. Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma. Cancer Res. 1995;55:817-822.
26. Schally AV, Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol. 1999;141:1-14.
27. Zhang F, Aft RL. Chemosensitizing and cytotoxic effects of 2-deoxy-D-glucose on breast cancer cells. J Cancer Res Ther. 2009;5:S41-S43.
28. Gründker C. Cytotoxic luteinizing hormone-releasing hormone conjugates and their use in gynecological cancer therapy. Eur J Endocrinol. 2000;143:569-572.
29. Gründker C, Völker P, Griesinger F, et al. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. Am J Obstet Gynecol. 2002; 187:528-537.
30. Priebe A, Tan L, Wahl H, et al. Glucose deprivation activates AMPK and induces cell death through modulation of Akt in ovarian cancer cells. Gynecol Oncol. 2011;122:389-395.
31. Simons AL, Ahmad IM, Mattson DM, et al. 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res. 2007;67:3364-3370.
32. Singh D, Banerji AK, Dwarakanath BS, et al. Optimizing cancer radiotherapy with 2-deoxy-D-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol. 2005;181:507-514.
33. Loar P, Wahl H, Kshirsagar M, et al. Inhibition of glycolysis enhances cisplatin-induced apoptosis in ovarian cancer cells. Am J Obstet Gynecol. 2010;202:e1-e8.
34. Maschek G, Savaraj N, Priebe W, et al. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res. 2004;64:31-34.